Hereditary spherocytosis pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
Line 21: Line 21:
** Approximately 50% of [[Patient|patients]] with severe [[Recessive gene|recessive]] [[hereditary spherocytosis]] have a [[point mutation]] at the [[Genetic code|codon (969)]] resulting in [[amino acid]] substitution ([[alanine]]/[[aspartic acid]]) at the corresponding site in [[Spectrin, alpha 1|apha spectrin]] [[protein]] leading to [[Defect|defective]] [[Binding (molecular)|binding]] of [[spectrin]] to [[Band 4.1|protein 4.1]].
** Approximately 50% of [[Patient|patients]] with severe [[Recessive gene|recessive]] [[hereditary spherocytosis]] have a [[point mutation]] at the [[Genetic code|codon (969)]] resulting in [[amino acid]] substitution ([[alanine]]/[[aspartic acid]]) at the corresponding site in [[Spectrin, alpha 1|apha spectrin]] [[protein]] leading to [[Defect|defective]] [[Binding (molecular)|binding]] of [[spectrin]] to [[Band 4.1|protein 4.1]].
* '''Akyrin deficiency'''
* '''Akyrin deficiency'''
** Ankyrin is the principal binding site for spectrin on the red blood cell membrane.
** [[Ankyrin]] is the principal [[binding site]] for [[spectrin]] on the [[red blood cell]] [[Cell membrane|membrane]].
** Ankyrin gene is located on chromosome 8, therefore translocation of chromosome 8 or deletion of short arm of chromosome 8 can lead to hereditary spherocytosis.
** [[Ankyrin]] [[gene]] is located on [[Chromosome 8 (human)|chromosome 8]], therefore [[Chromosomal translocation|translocation]] of [[Chromosome 8 (human)|chromosome 8]] or [[Deletion (genetics)|deletion]] of [[Chromosome 8 (human)|short arm of chromosome 8]] can lead to [[hereditary spherocytosis]].
** Ankyrin deficiency leads to decreased incorporation of spectrin, leading to a proportional decrease in spectrin content as well despite the normal synthesis of spectrin.
** [[Ankyrin]] [[deficiency]] leads to decreased incorporation of [[spectrin]], leading to a proportional decrease in [[spectrin]] content as well despite the normal synthesis of [[spectrin]].
* '''Band 3 deficiency'''
* '''Band 3 deficiency'''
** Band 3 deficiency is seen in 10-20% of patients with mild to moderate autosomal dominant hereditary spherocytosis.
** [[Band 3]] [[deficiency]] is seen in 10-20% of [[Patient|patients]] with mild to moderate [[Dominance relationship|autosomal dominant]] [[hereditary spherocytosis]].
** Band 3 deficiency is considerably greater in older RBCs due to unstable nature of band 3 protein.
** [[Band 3]] [[deficiency]] is considerably greater in older [[Red blood cell|RBCs]] due to unstable nature of [[band 3]] [[protein]].
* '''Protein 4.2 (Pallidin) Deficiency'''
* '''Protein 4.2 (Pallidin) Deficiency'''
** Protein 4.2 deficiency leads to abnormal RBC morphology including spherocytes, elliptocytes or sphero-ovalocytes.
** [[Protein 4.2]] [[deficiency]] leads to abnormal [[Red blood cell|RBC]] [[morphology]] including [[Spherocytosis|spherocytes]], elliptocytes or sphero-ovalocytes.
** Its deficiency is relatively common in japan.
** Its [[deficiency]] is relatively common in japan.
** A point mutation causing complete absence of protein 4.2 is associated with typical hereditary spherocytosis phenoype.
** A [[point mutation]] causing complete absence of [[protein 4.2]] is associated with typical [[hereditary spherocytosis]] [[phenotype]].
* '''Red Blood Cell Antibodies'''
* '''Red Blood Cell Antibodies'''
** Zaninoni et all found RBC antibodies in 61% of patients with hereditary spherocytosis using a mitogen stimulated direct antiglobulin test.<ref name="pmid26259504">{{cite journal| author=Zaninoni A, Vercellati C, Imperiali FG, Marcello AP, Fattizzo B, Fermo E et al.| title=Detection of red blood cell antibodies in mitogen-stimulated cultures from patients with hereditary spherocytosis. | journal=Transfusion | year= 2015 | volume= 55 | issue= 12 | pages= 2930-8 | pmid=26259504 | doi=10.1111/trf.13257 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26259504  }}</ref>
** Zaninoni et all found [[Red blood cell|RBC]] [[antibodies]] in 61% of [[Patient|patients]] with [[hereditary spherocytosis]] using a [[mitogen]] stimulated [[Coombs test|direct antiglobulin test]].<ref name="pmid26259504">{{cite journal| author=Zaninoni A, Vercellati C, Imperiali FG, Marcello AP, Fattizzo B, Fermo E et al.| title=Detection of red blood cell antibodies in mitogen-stimulated cultures from patients with hereditary spherocytosis. | journal=Transfusion | year= 2015 | volume= 55 | issue= 12 | pages= 2930-8 | pmid=26259504 | doi=10.1111/trf.13257 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26259504  }}</ref>
** They concluded that the more evident hemolytic pattern in patients with RBC autoantibodies suggests that these antibodies have a pathogenic role in RBC opsonization and removal by spleen.
** They concluded that the more evident [[Hemolysis|hemolytic pattern]] in [[Patient|patients]] with [[Red blood cell|RBC]] [[Autoantibody|autoantibodies]] suggests that these [[antibodies]] have a [[Pathogenesis|pathogenic role]] in [[Red blood cell|RBC]] [[Opsonin|opsonization]] and removal by [[spleen]].


==References==
==References==

Latest revision as of 22:02, 4 December 2018

Hereditary spherocytosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hereditary spherocytosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hereditary spherocytosis pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hereditary spherocytosis pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hereditary spherocytosis pathophysiology

CDC on Hereditary spherocytosis pathophysiology

Hereditary spherocytosis pathophysiology in the news

Blogs on Hereditary spherocytosis pathophysiology

Directions to Hospitals Treating Hereditary spherocytosis

Risk calculators and risk factors for Hereditary spherocytosis pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

The defects in hereditary spherocytosis lie in the cell membrane. The proteins essential for integrity of cell membrane structure lie immediately under the lipid bilayer, horizental alpha & beta spectrin molecules form heterodimers with linkage to vertical elements including ankyrin, proteins 4.1 & 4.2 and band 3 (transmembrane protein). The shorter the lifespan of red blood cells, the worse the clinical effects. Spectrin protein is a tetramer composed of alpha & beta dimers, its deficiency is most frequently seen in hereditary spherocytosis. Spectrin deficiency can result from impaired synthesis of spectrin or from qualitative or quantitative defects in other proteins that integrate proteins into red blood cells. Ankyrin is the principal binding site for spectrin on red blood cell membrane, its deficiency leading to decreased incorporation of spectrin, leading to proportional decrease in spectrin content as well despite normal synthesis of spectrin. Band 3 deficiency is seen in 10-20% of patients with mild to moderate autosomal dominant hereditary spherocytosis and is considerably greater in older red blood cells. Protein 4.2 (Pallidin) deficiency leads to abnormal red blood cell morphology including spherocytes, elliptocytes or sphero-ovalocytes, it is relatively common in japan. Red blood cell antibodies may also have a pathogenic role in red blood cell opsonization and removal by spleen.

Pathophysiology

References

  1. Bolton-Maggs, P H B (2004). "Hereditary spherocytosis; new guidelines". Archives of Disease in Childhood. 89 (9): 809–812. doi:10.1136/adc.2003.034587. ISSN 0003-9888.
  2. Perrotta, S.; Della Ragione, F.; Rossi, F.; Avvisati, R. A.; Di Pinto, D.; De Mieri, G.; Scianguetta, S.; Mancusi, S.; De Falco, L.; Marano, V.; Iolascon, A. (2009). "-spectrinBari: a truncated  -chain responsible for dominant hereditary spherocytosis". Haematologica. 94 (12): 1753–1757. doi:10.3324/haematol.2009.010124. ISSN 0390-6078.
  3. Maciag M, Płochocka D, Adamowicz-Salach A, Burzyńska B (2009). "Novel beta-spectrin mutations in hereditary spherocytosis associated with decreased levels of mRNA". Br J Haematol. 146 (3): 326–32. doi:10.1111/j.1365-2141.2009.07759.x. PMID 19538529.
  4. Zaninoni A, Vercellati C, Imperiali FG, Marcello AP, Fattizzo B, Fermo E; et al. (2015). "Detection of red blood cell antibodies in mitogen-stimulated cultures from patients with hereditary spherocytosis". Transfusion. 55 (12): 2930–8. doi:10.1111/trf.13257. PMID 26259504.

Template:WH Template:WS